Teva receives FDA approval to market generic asthma treatment
Teva is one of ten companies to obtain FDA approval for a generic version of Merck's asthma and allergies drug Singulair.
Teva obtained approval for both tablet and oral granule forms of Singulair. Teva, Mylan Inc.(NYSE: MYL), and Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) generic subsidiary Sandoz will reportedly launch cheaper generic versions of the drug, which will jointly win 66% of the market.
Montelukast, the active ingredient in the drug, is in a class of medications called leukotriene receptor antagonists. It works by blocking the action of leukotrienes, substances in the body that cause the symptoms of asthma and hay fever (allergic rhinitis).
Published by Globes [online], Israel business news - www.globes-online.com - on August 5, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012).
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options